Thursday 15 October 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
2.27
0.02
+0.89%
Follow ELDN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.30 | 13.19 | 5.63 | 7.54 | 46.57 | 20.07 | 9.19 | 14.41 | 12.42 | 7.40 |
Net Debt/EBITDA |
(0.46) | 1.32 | 0.92 | 0.63 | 6.25 | 2.31 | 1.43 | 1.20 | 1.99 | 1.60 |
Debt/Assets |
288.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.28) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.87 | 1.14 | 0.85 | 0.87 | 0.67 | 0.84 | 0.32 | 0.34 | 1.31 | 1.37 |
Capex/Depreciation |
0.03 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (19.17%) | (156.79%) | (82.87%) | (133.66%) | (22.80%) | (19.46%) | (70.89%) | (652.92%) | (518.40%) | (63.56%) | |
| (16.35%) | (118.76%) | (74.19%) | (114.54%) | (21.92%) | (18.77%) | (66.81%) | (128.16%) | (27.16%) | (26.34%) | |
ROIC |
0.00% | (381.60%) | (578.13%) | (1,488.41%) | (15.11%) | (29.11%) | (198.99%) | 0.00% | 0.00% | (1,511.24%) |
Return on Tangible Assets |
208.13% | (74.59%) | (119.64%) | (185.01%) | (20.16%) | (41.11%) | (165.84%) | (223.11%) | (27.38%) | (38.87%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.09 | 0.11 | 0.00 | 0.25 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(231.08) | (57.41) | (23.75) | (21.12) | (10.48) | (1.95) | (1.99) | (1.61) | (0.97) | (0.76) |
Cash per Share |
52.44 | 66.52 | 25.91 | 13.40 | 78.70 | 5.72 | 3.95 | 2.08 | 2.89 | 1.63 |
Shareholders Equity per Share |
(126.85) | 74.79 | 28.94 | 14.43 | 131.35 | 11.07 | 5.89 | 0.29 | 2.43 | 1.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(126.85) | 74.79 | 28.94 | 14.43 | 131.35 | 11.07 | 5.89 | 0.29 | 2.43 | 1.67 |
Free Cash Flow |
(4.92) | (14.93) | (11.89) | (13.86) | (15.21) | (28.91) | (28.42) | (39.53) | (47.27) | (62.34) |
Working Capital |
(2.75) | 17.56 | 11.74 | 8.65 | 113.15 | 83.95 | 53.04 | 52.23 | 132.15 | 117.34 |
Capital Expenditures |
0.00 | 0.01 | — | — | — | — | — | — | — | — |
Net Current Asset Value |
(2.75) | 17.56 | 11.74 | 8.51 | 109.04 | 81.79 | 50.91 | (25.73) | 84.47 | 103.46 |
| Other line items | ||||||||||
Quick Ratio |
0.29 | 12.02 | 5.12 | 6.65 | 45.99 | 19.28 | 8.71 | 13.12 | 12.11 | 7.27 |
Depreciation/Fixed assets |
1.13 | 0.88 | 0.79 | 409.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Cash ROIC |
(264.34%) | (40.63%) | (43.30%) | (75.90%) | (4.99%) | (11.62%) | (20.22%) | (67.79%) | (18.30%) | (23.08%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(231.13) | (57.44) | (23.75) | (21.12) | (10.48) | (1.95) | (1.99) | (1.61) | (0.97) | (0.76) |
Capex per Share |
0.05 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 0.18 | 0.18 | — | — | — | — | — |
Average Payables |
0.77 | 0.38 | 0.55 | 0.51 | 0.85 | 1.59 | 2.01 | 1.58 | 3.40 | 4.73 |
Average Assets |
34.59 | 11.04 | 18.96 | 13.98 | 104.06 | 183.87 | 131.67 | 90.93 | 133.24 | 173.21 |
Average Common Equity |
29.50 | 8.37 | 16.97 | 11.98 | 100.03 | 177.30 | 124.09 | 17.85 | 6.98 | 71.77 |
Capex to Sales |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Columns are period end dates